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At its plenary sittings of 18 June 1980 and 16 January 1981 
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- the motion for a resolution tabled by Mr Gherqo and others, 
pursuant to Rule 25 of the Rules of Procedure;! on the state 
of implementation of the EEC directives on proprietary med-
icinal products and measures to be adopted for the free move-
ment of pharmaceuticals between Member States (Doc. 1-243/80) 
and 
-the motion for a resolution tabled by Mrs Krouwel-Vlarn,and 
others, pursuant to Rule 25 of the Rules of Procedure~Jon 
the production and use of pharmaceutical products 
(Doc. 1-817/80), 
to the Committee on Ec~nomic and Monetary Affairs as the 
committee responsible, ~nd to the Committee on the Environment, 
Public Health and Consu~er Protection for its opinion. 
At its meetings of 21 October 1980 and 18 February 1981, 
the Committee on Economic and Monetary Affairs appointed 
Mr Deleau rapporteur on these two mohions for resolutions. 
The Committee on Economic a~d Monetary Affairs considered the 
draft report at its meetings of 2~ and 30 November 1982. At its 
meeting of 30 November 1982, it unanimously adopted the motion for 
\ 
a resolution. 
er~~~n!: Mr Jacques MOREAU, chairman; Mr DELEAU, vice-chairman and 
rapporteur; Mr BONACCINI, Mr CAROSSINO (deputizing for Mr LEONARDI), 
I 
Mrs DESOUCHES, Mr FRANZ, Mr de GOEDE, Mr HERMAN, Mr HOPPER, Mrs LiliN 
(deputizing for Mr SCHWARTZENBERG>, ~r MORELAND (deputizing for 
Mr de FERRANTI>, Mr MULLER-HERMANN <deputizing for Mr COLLOMB), 
Mr PURVIS (deputizing for Miss FORSTE~), Mr VAN ROMPUY, Mr VERGEER, 
Mr WELSH and Mr von WOGAU. 
The opinion of the Committee on t~e Environment, Public Health 
and Consumer Protection is attached. 
1 currently Rule 47 
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A. 
The Committee on Economic and Monetary Affairs hereby 
submits to the European Parliament the following motion for 
a resolution together with explanatory statement: 
MOTION-FOR-A. RESOLUTION 
on the production and use of pharmaceutical products in the 
Community 
The.E~ropean.Parliament, 
- having regard to its motions for resolutions (Docs. 1-243/80 
and l-817/80), 
- having regard to the report of the Committee on Economic and 
Monetary Affairs and the opinion of the Committee on the Environment, 
Public Health and Consumer Protection (Doc. 1-979/82), 
1. Considers that the European pharmaceutical industry constit-
utes an important industrial sector that has been able, in 
spite of the economic crisis, essentially to maintain its 
competitivity, employment levels and export capacity: 
2. Stresses both the potential and the special situation of 
the Community's pharmaceutical industry, and considers that 
its activities must, in view of their implications for public 
health and the volume of public health-care expenditure, 
be rigorously assessed, albeit in a constructive spirit: 
3. Considers that in the context 
- - -
strategy, a European strategy 
. . . 
industry must be worked out: 
?f_g~al industrial 
for the pharmaceutic~! 
... 
thds must reconcile the promotion of this sector, confronted 
as it is with high research costs and stiff international 
competition, with the implicit EEC Treaty objective'of 
improving public health at the lowest cost and in the best 
conditions possible: 
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4. Str'~$'S that the f~ture of the pharmaceutical industry wi~L Q,P,nA 
principally on its capacity for innovation; that in view of the 
gr9wing cost of research, the pharmaceutical industry must tperef~ft 
establish its priorities and should orient its research effort ICGQr~­
i"gly; that the Community institutions, without substituting thtt~ own 
activities for the responsibilities of private research laboratories, 
must henceforth assume a coordinating function in this sector of 
research; 
5. Calls in particular on the Commission to prov1de the incentives· 
necessary in order to carry the vario~s e•isting pharmaceutical research 
programmes to their conclusion, an~ tA esttP~ish basic guidelines-for 
pharmaceutical research in areas th1t h'~'- hi~h,rto been neglected but 
where real needs exist; 
Calls on the Commission to conduct ~ review pf the various national 
pharmaceutical research program~e~ tp ~ee wht,ther coordination is 
possible so as to avoid duplication. ~nq filL '"Y gaps that may b• found 
to exist; 
6. Notes that legal protection for phar~aceuti,al inventions is in 
practice attenuated by the length of test-periods, and calls on the 
Commission to investigate, possiblY on the lines of procedures 
envisaged in the United States, eff,ctive •eans of strengthening 
this indispensable legal protection ~nd also means of extending the 
facilities for product testing anq screeninQ; 
7. Calls on the Commission to develop t~e Com~on "'rket in pharmaceutical 
products in such a way as to enable ethical, generic and mass consump-
tion products to find th,ir natural balance in re~ponse to the needs 
of the market and the interests of public healt~; 
8. Insists that the Community contribute to estabLis~ing the necessary 
conditions for the development of an authentic external trade policy, 
which would be of considerable value to the European pharmaceutical 
industry; also calls on the Commission to seekf in the. appropriate 
international bodies, basic arrangements for cooperation with developing 
countries that can reconcile, in the pharmaceutical field, the needs 
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of these countries, which consume less than 20X of world production, 
their requirements, and the concern of the pharmaceutical undertakings 
for basic stability and profitability; 
9. Calls on the Commission to ensure that the quality standards required 
of pharmaceutical products in the Community countries will apply to 
all exported products and will be subject to appropriate scrutiny 
jointly with the World Health Organization; 
1m. Recalls that the pharmaceutical industry is characterised by a high 
level of concentration on the part of producers and a high incidence 
of monopoly purchasers. This makes it particularly important for 
the Commission to monitor vigilantly the application of the rules of 
competition in this sector, in regard to both the private companies and 
the public agencies, 
Calls on the Council speedily to adopt the proposal for a regulation 
on the control of concentrations as a means of securing the position of 
SMUs, which have their special place in the sector of generic drug 
production and mass-consumption products, and are a dynamic and 
innovating element; 
11. Believes that the market for pharmaceutical products is vulnerable to 
disruption by parallel imports and that this could best be solved by 
opening the market to cross-border transfers from ~gl• European 
production centres. Such a liberalization would help small and medium-
sized undertakings to make a dynamic contribution to the production of 
general drugs and mass consumption products by making it impossible for 
national authorities to restrict purchasing and distribution; 
12. Stresses that it will be in the joint interest of consumers and the 
industry for the pharmaceutical industry to benefit from the opening 
up of the European market; 
Calls on the Commission vigorously to pursue its work of harmonization 
of legislation in this field, and on the Council to assist, in particular 
by adopting without delay the recent proposal for a directive on the 
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harmonization of marketing authorizations, as the essential first step 
towards a market in pharmaceuticals genuinely open to the free -.v~nt 
of goods; 
Considers that it would make a significant impact on the Community 
public if harmonization of legislation on the .issuing of phar.a~ 
ceuticals on prescription were to be introduced, and calls on the 
Commission to submit an appropriate proposal; 
Calls on the Commission to oppose all unjustified attempts to wall off 
markets; 
13. Considers it indispensable to bring about real transparency of the 
market in pharmaceuticals, both from the legal point of view, in 
particular as regards parallel imports, and from the fiscal point of 
view; 
In this connection again asks the CoMmission to submit a proposal on 
transfer prices as an indispensable instrument for equalization of 
competition and rationalization of undertakings; 
14. Considers that price formation on the market in pharmaceuticals is 
unsatisfactory; 
Considers that the considerable disparities in prices, whether they are 
the result of non-observance of the rules of competition, of the diversity of 
nation~l price-fixing arrangements and drug prices, or of variations 
in wholesalers' and pharmacis~s' margins as between Member States, 
violate the basic Treaty objective of securing a balanced market that 
meets the need to provide the highest standard of public health care 
at the lowest cost and in the best conditions possible; 
15. Therefore calls on the Commission to proceed as soon as possible, as 
requested by the European Parliament in its previous resolution, with 
a study of the compatibility with the EEC Treaty of the different· 
national systems for monitoring the prices of pharmaceuticals; 
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16. Also calls on the Commission to seek with more determination that it 
has hitherto shown arrangements for coordination with the national 
authorities responsible for monitoring the prices of drugs, with a 
view to harmonizing national systems, since artificial importing 
channels will otherwise be perpetuated; 
17. Stresses that any European strategy on pharmaceuticals aimed at 
improving public health must also concentrate on the conditions under 
which drugs are used, whilst taking account of the often decisive 
influence of social protection systems, and help to improve training 
and information for practitioners and drug users; 
18. Calls on the Commission to consider arrangements for the general 
introduction in the Community of compulsory post-graduate and follow-
up courses to provide doctors with training in the therapeutical 
field and in the field of drug control, and for wider'access to relevant 
data banks; 
19. Also calls on the Commission to study the possiblity of implementing, 
with the cooperation of the national authorities, an information and 
education campaign covering the proper use of pharmaceutical products, 
taking due account of the different practices in the use of drugs as 
between Member States; 
20. Points out that in view of the particular nature of drugs, advertising 
for pharmaceuticals must be subject to special rules; 
Therefore again calls on the Commission to submit a proposal in this 
area; 
Considers that abusive trading practices by certain Laboratories must 
be severely condemned; 
2t. Calls on the Commission to study the prospects and scope for self-
medication; 
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Calls also on the Commission to produce full and harmOhiz•d 
statistics on the pharmaceuticals sector as a whole, ao 
that the use of drugs and their impact on health and Oft 
public health expenditure in the Community can be monitored 
and compared in precise detail in future; 
22. Instructs its President to forward this resolution to the 
Council, the Commission and the parliaments of the Member 
States of the Community. 
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B. 
EXPLANATORY STATE"ENT 
INTRODUCTION 
The two motions for resolutions1 on the pharmaceuticals sector underlying 
this report relate to a wide range of questions such as the structure of 
competition, the volume of pharmaceutical production, production guidelines, 
price formation, advertising, information for practitioners and users and ways 
of securing effective free movement of drugs in the EEC. 
The European Parliament adopted in 1978 a report2 on the subject dealing 
in some depth with a number of matters, including in particular the suppty 
structure in the sector and price and profit levels. One of the conclusions 
reached in this report and the hearings that preceded it was that, given the 
special situation of the pharmaceuticals industry, it would be appropriate to 
adopt a position of well-informed vigilance before coming to any conclusions 
as to the guidelines to be followed in this sector. 
It is therefore clear that if this new report by the Committee on Economic 
and Monetary Affairs on the production and use of pharmaceu\ical products is to 
prove'its worth and avoid duplication on certain matters or controversies that 
have already been highlighted, it must combine a study of matters previously 
raised, such as price levels, advertising and competition, with an overall 
view of the future of the pharmaceutical industry in the !EC. 
The purpose of this report is therefore to consider the production and use 
of pharmaceuticals in the wider context of a European pharmaceuticals policy 
comprising, as far as possible: 
- promotion of this major industrial sector, confronted as it is with ~igh 
research costs and international competition, and 
the improvement of public health at the lowest eost and in the best conditions 
possible. 
The new report should thus constitute an appraisal of the matters raised in 
the report adopted in 1978 and an analysis of future prospects for the sector. 
1 Docs. 1-243/80 and 1-817/80 
2 Report on the manufacture, distribution and use of pharmaceutical preparations 
by Mr DE KEERSMAECKER (Doc. 664/78) 
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We shall consider in turn production guidelines, marketing conditions and 
the circumstances in which drugs are used. 
I. PRODUCTJON GUIDELINES 
The pharmaceutical industry in the Community is an important traditional 
sector that has so far succeeded in maintaining its dynamism. Indeed, the 
European pharmaceutical industry now occupies a major position in world trade, 
and its activities account for a very high export volume. It is a sector 
with a very high added value, is a low polluter, a low energy consumer, 
and employs some 315,000 individuals in the eec, a high proportion of them 
highly qualified. 
However, the European pharmaceutical industry today faces a double set 
of difficulties. The first arises from the grow1nt cost of research. While 
pharmaceutical research went through a period of major expansion until into 
the sixties, it is becoming increasingly difficult to invent useful new 
medicines. Each therapeutic breakthrough presupposes an·extended period of 
long and costly research before any marketable product can be produced. 
At the same time the European pharmaceutical industry is beginning to 
be exposed to international competition, in particular competition from 
Japan, which is likely to prove intensive. In fact the Japanese industry, 
the volume of whose exports has hitherto been MOdest, is now investing 
heavily in this sector. 
It therefore seems appropriate, especially ~hen the implications of 
pharmaceutical production for the social security expenditure of the states 
is taken into account, to implement, before it is too late, a European 
strategy for the pharmaceutical sector that reconciles as far as possible. 
the improvement of public health, the vitality of the sector, and the need 
to restrain public spending and uphold the rules of competition la·id down 
in the Treaties. 
This strategy could be pivoted on the following four basic approaches: 
1. Research promotion 
The essential characteristic of the pharmaceutical industry is that 
competition takes the form of innovation and the substitution of one 
product for another. This highlights the important role played by research 
in the sector. The implementation of a European research strategy in the 
field of pharmaceuticals presupposes the establishment of appropriate 
facilities and guidelines. 
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Research financing is a major item in the budget of pharmaceutical 
undertakings, or at least of those that undertake research activities and do 
not confine themselves to manufacturing and distributing generic or mass-
consumption products. The need to devote Large sums to research must also be 
taken fully into consideration when evaluating the profits realized by the 
industry. 
Research costs, given their overwhelming importance in the present 
context of competition, obviously call for an element of coordination. A 
high level of coordination of research investment in European pharmaceutical 
industries is clearly desirable. In fact, the Commission notes in a recent 
communication on scientific and technical research in the Community1 that a 
certain dissipation of effort is characteristic of this field. The Commission 
should, therefore, without in any sense substituting its own activity for the 
responsibility, free choice and risks of the industries concerned, encourage 
the Latter to establish research priorities. As the Commission recommends in 
its communication on a Community strategy to develop Europe's industry2, 
'Long-term projections ••• must be prepared, and essential industries ••• 
must have the technologies they need in good time so that they can continue 
to be a source of wealth and employment'. 
The coordination of investment in research should also apply to 
pharmaceutical Laboratories and private and government research establishments, 
as the motion for a resolution states3• 
It would be appropriate to determine whether the Commission now has 
sufficient resources4 to play an effective coordinating and pioneering role 
in the research sector. 
1 COM<81) 574 final: Scientific and technical research in the European Community; 
2 COM(81) 639 final, p.10; 
3 Doc. 1-817/80, paragraph 7; 
4 The Community budget now devotes some 1.6% of appropriations to research and 
development. Within CREST there is a committee on medical and public health 
research; a Council decision of 18.3.1980- OJ L 78, p.24- drew up a research 
programme in the field of medical and public health research consisting of four 
concerted multi-annual projects. A research programme on methodological research 
to improve drug control and monitoring of pharmaceutical products has also been 
forwarded by the Commission to the Council. 
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The Community can also orient research in the pharmaceutical field to 
the future needs of the industry, having regat.d to its competitive po•i,ioh, 
and also to the public health objectives implicit in the EEC Treaty. 
Freedom of research in laboratories is indispensable to the very •u.cctss 
of their research effort, the complexity of which is well known. It often 
happens, however that research in pharmaceutical laboratories tends to be 
oriented to criteria of profitability, either in developing drugs for 
treating widespread illnesses, or turning out products not significantly. 
·different from existing drugs, but having the advantage of relative novelty. 
It would, however, be going too far to say that the numbers of drugs 
marketed was growing uncontrollably.In France, for examp~e, the nUMber of 
drugs has gone from-25,000 in 1930 to 8,500 in 1977 and, according to. INSEE 
statistics, between 1971 and 1979 consullt~tion of pharmaceuticals increased 
by only 7.1X in volume terms per year. lt is the rising cost of hospitalization 
that accounts for the growth in health care expenditure, rather than strictly 
pharmaceutical expenses. 
It remains the case, however, that the effort should be 111de -to determine 
how the Community can play a guiding role in research; particularly 1n the less 
profitable fields such as rare diseases or tropicil diseases in the developing 
countries. 
2. Legal protection for pharmaceutical inventions 
1 
At present the period of legal protection under patent pursuant to the 
Munich Convention of 5 October 1973 on the issue of European patents and the 
Luxembourg Convention on European patents for the Co..on Market of 15 February 
1975 is 20 years. This seemingly long period is in fact considerably' shortened 
by lead times of up to 10 years that can elapse betMttn discovery and'sale of 
a product, given the growing number and severity of tests that must be carried 
out before a drug is marketed. If the period of exclusive rights is too_ ihort, 
the profitability of an invention is therefore considerably reduced, and 
this in turn inhibits the research effort. 
The question 1;here·fore arises, Qiven the special sitaation of the 
pharmaceutical sector, as to whether the .EEC should introduce the so-called 
'stop the clock' system now under study in the United States and consisting 
of suspending expiry of the 20-year period during the entire test period to 
a maximum of 7 years1• 
PATENT RESTORATION ACT, 1981 
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This extra protectio'ri seems all the mor·e i'ndispEmsable in that, although 
the European Court of Justice can affirm the existence of the right of patent, 
the exercise of this right is often attenuated by the fact of the rules of 
free movement of goods and the exhaustion of patent rights, especially in the 
case of parallel imports. It is hardly acceptable that parallel importers should 
sometimes benefit from substantial windfall profits when they contribute 
nothing to the research effort. 
3. Balanced production of pharmaceuticals, generic and mass-consumption products 
Production breaks down into three main groups of products: pharmaceuticals, 
generic drugs and mass-consumption drugs, each of which meets a particular set 
of needs. 
Pharmaceuticals, in the form of patented inventions essential to public 
health care,are certainly the major element in production and a sign of the 
competitivity of the industry. 
However, by no means negligible, resources are devoted to the production 
of generic drugs, i.e. drugs that are now standard products and can be freely 
manufactured without a trade-name. It is certain that this sector of production 
has been unduly neglected for obvious reasons of profitability. Since they are 
sold at a lower price, having become a standardized product (approximately 30X 
cheaper> these products are evidently less attractive to laboratories and 
pharmacies. It would therefore be appropriate to give an impetus to the 
production of generic drugs in those cases where the same therapeutic effect 
l 
can be obtained at a lower social-security cost. It would be wrong, however, 
to believe that demand could be satisfied by generic drugs alone; this would 
be to take a short-term view that would compromise future prospects in return 
for a purely financial immediate saving in public expenditure. To orient 
production exclusively on generic drugs would irreversibly compromise the 
future prospects and competitivity of the industry, and would be detrimental 
to health care in the long run. 
The same problem arises with mass-consumption of 'family' products, as 
opposed to ethical products. The representatives of the industries stress the 
economies that this type of drug make.s possible. Self...;.medication should not, 
however, be encouraged except within reasonable bounds, taking the level of 
information available to the user and the risk -to health of drug abuse into 
account. 
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Careful consideration of the d&licate subject of the balance in 
pharmaceuticals production, bearing in mind that the future as well is th~ 
present state of the industry is at stake, will be necessary to pin~bir\1: 
the m•asures that will be needed in terms of advertising, training ~f 
medical practioners <who are often unaware of the existence of generio 
drugs>, the control of drugs, their inclusion/non-inclusion in social-
security reimbursement lists, and harmonization of regulations on compulsory 
prescriptions, if an optimum balance is to be obtained in the production of 
these three groups of drugs. 
4. Exterr\al trade policy for the pharmaceutical .slc.t.or 
The recent Commission communication oft a §trategy to develop Europe's 
industry1 stresses that the Commission ~ois nHt ~t ~resent have any mechahism 
for promoting either exports or externil invettiiht, But the Community cannot 
be satisfied with separate initiatives an~ ffiust trt to step up coordination of 
its efforts. This general rule obviouslf i~blie~ to the pharmaceutical sector. 
Clearly an effort should be m'Si to it~p U~ fxports of European 
pharmaceuticals to the USA and Japan. 
As to the developing countries, the c~unity should approach the 
appropriate international organizatiohs sUch as uNttAD or WHO with a view to 
reconciling the needs of these countritts, th•H ~equirements, and the 
pharmaceutical undert•kings' concern l6r Mini-um stability and profitability. 
At present 80% of world pharmaceutical production is consumed in the 
industrialized countries and less than ~01 in developing countries. 
II. MARKET CONDITIONS 
The success of a European strategy for the pharmaceutical industry that 
will help to maintain competitivit1 in the s~ctor arid meet public health 
requirements at lowest cost presup~~ses that the ri~ht conditions obtain to 
securing an open, transparent and otderl1 market. 
Without going into a detailed analysis of thi special structure of the 
market in pharmaceutical J)roducts2 it 11Ht b~ liHfUl td r~e•H some of the 
·salient features. 
1 COM(81) 639 final 2, p.14 
2 See report by Mr DE KEERSMA£KER, Doc. 664/1$ 
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,.. By virtue of 1ta considerable raaearch costa, the sector. diaplaya a 
grCA~ing tendency to concentration. The pharUceuthal ·1ndustf'7 ta character- · 
tzed by the fact that a liatted nuaber of producers and ~~eta alone 
I 
account for ·a v~ry large part of the aarket1• 
This ol1gopolization and concentration of the industry under Laroe 
transnational undertaking• obviously entails tha risks of a ~inant·poaitfonf 
t'e .ore so tn that the prices of phar.ac~tcal product• are highly 1neLaittl. 
lt ahould therefore again be atressed that thta structure aakea tt 
necessary for the Coaatsston to pay particularly cloae attention to the 
observance of the rules of coapetttion of the Treattea. And •t does so; 
.areover, the Jud~nts of the European Court of Justice in thfs fteld have 
been extr .. ely conafstent and a tubatanttal body of case lew 11 accuaulattng 
year by year. 
However, the fairly unique and re\attve character of oltgopoliaatton tn 
the phar•aceuttcal field •ust be stressed. ln fact, ~tnant poatttons .tn thia 
sector arise fro. the fact of the 1~rtance of innovation itself, an essential 
factor tn ca.pet1tton, albeit a precarious one that ta confined to a tingle 
product or a spectftc therapeutic area. 
Roreover thfa situation ta not neceaaartly prejudtcfal to publtc health 
etnce it et1aulatea research and leas to new inventions b1 coapet4ne coapant•• 
tn turn. 
\ 
lt fa to be hoped nevertheleas that the regulation on the control of 
concentration• will soon be adopted by the Council tn the ... nded version that 
has just been aubattttd. This regulation could in fact play a useful role in 
guaranteeing the viabfltty·of the SMUt vbtch, tf not tn the reaearcb sector, 
then at least in the production of genertc and .. aa-contuaption drugs, play 
an t~ortant roLe. 
1. An eten market 
the relative untqueneas of the pha~ceuttcal sector ta by no aeans an 
Obstacle to the opening up of the .. rket. As tn other sectors of 1nduttry, 
tt 11 eaaenttal for the European pha~ceut1ca\ industry to have the advantaotl 
of an effective european aarket. 
1 ln france .the nuaber of laboratortea fel\ fraa 2,000 to 350 in the apace of 
30 years. · 
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The Member &tatet havt t~d often •aintained walltd•b~f ilrktts oh the 
pretext of public health require~ents. The application 6f Article 36 of tha 
' 
EEC treaty, which has been diverted from its real objective; hal eftiN Ltd, 
as Parliament's motion for a resolution COoc. 1·243180>1 points out, tl •~ 
actual reduction in health care standards, either because thf opportunity 
for the entire population of the Community to use new and more tfftcttv• 
products to treat disease is prevented or considerably delayed, or because 
products remain in circulation after some Member States have found them to 
be potentially harmful. 
It will therefore be essential to pursui the objective of harmoniz1ng 
national legislation governing undertakings on the initiative of the 
Commission as regards the production, authar1altion, registration and 
distribution of pharmaceuticals. Here, the recent Commission proposal for a 
directive on the mutual recognition of •at-ketihq authorizations2 would 
constitute an important step in this di~lttion; and the European Parliament 
can only ask the Council to adopt this •ro,o.;L without delay. 
It would also make a signific•nt pub~ic iM-act in the Ca.eunity·}f 
harmonization of legislation on the aviil,bilitY of drugs witho.ut 
pres,ription were to be introduced in the near fUture. 
Similarly the Commission's recent proposal for a regulation establishing 
a Community tr~mark3 should be adopted. Trade protection for the.quality of 
' 
a product during and beyond the protection pro~idld by patent is indispensable, 
particularly in the health field. thi fKiste~cl of a Ca..unity trad.-.ark 
can only facilitate the exercise of this riaht ih the C~ity as a whole, 
and would constitute a factor tending to the ••uilization of conditions 
of competition and the opening up o1 lnit'Uts; it would of courae be fo.r the 
European Court of Justice to senctibtl iny tradi ... lllark or patent abuses leading 
to the walling-off of markets. 
3. A transparent market 
1 
2 
As a corollary of the condition of an open .. rket, transparency is 
necessary both for observ4iltion df the rules of cbipethion and in .the interests 
of the consumer. 
Motion for a Resolution Doc. 1·243/SO; third recital ) 
Report by Mr von WOGAU, Doc. 1-246/81 
3 COM C80) 635 final 
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The requirement of transparency should apply mainly on one technical 
side to the composition of pharmaceuticals, as a means of outlawing changes 
in composition having no real therapeutic value, or artificial changes in 
denomination that make monitoring of the market more difficult and heighten 
the danger of drug confusion. 
Transparency must also apply with regard to parallel importt, which MUst 
be open to all importers provided they fulfil the required conditions set out 
in the Commission's communication1, in order to forestall all efforts to 
monopolize trade in these products. 
Finally, transparency will also be necessary from the fiscal·point of 
view for multinational pharmaceutical undertakings, as for all multinationals. 
It is regrettable that the Commission has still not submitted any proposals 
on transfer prices, since this would be an indispensable mechanism for 
equalizing competition and rationalizing undertakings. 
4. An orderly market 
The formation of pharmaceutical prices is somewhat pecultar, since it 
results from interaction between a number of suppliers and one principle 
customer, namely the social security system, given the predominant role 
played by the public authorities in fixing prices and listing drugs as 
eligible for reimbursement. This results in considerable price disparities 
in the Community. Whether they are attributable to the non-observance of the 
rules of competition by producers, to the various national price fixing 
systems for pharmaceuticals, or to variations in the margins of wholesalers 
and pharmacists, these price disparities are unacceptable in terms of health 
protection and health improvement. Moreover, current price disparities, 
aggravated by exchange rate variations, act as an impetus to parallel import 
channels between Member States resulting in a flow of windfall profits 
primarily to the importer. Moreover when prices are too low, pharmaceutical 
research possibilities are reduced. 
It is regrettable that the requests made by Parliament in its previous 
resolution2 have resulted in hardly any action being, taken. 
1 COM(81) 803 final 
2 Report by Mr DE KEERSMAEKER, Doc. 664/78, paragraphs 8, 9, 10 and 11 
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As the Commission points out1, fixing a price which is too low or 
excluding a drug from reimbursement constitute _as effective a barrier at 
the refusal of a marketing authorization. The Ca..ission has not yet 
reported to the European Parliament on the study it was asked to provide 
of the compatibility of the different national pharmaceutical price. 
monitoring systems. This omission is regrettable, and the Commission, in 
addition to its specific projects in this field, should inform the European 
Parliament on developments as a whole, and make whatever proposals it deems 
necessary. 
The European ~arliament had also a~ked the Commission to study ways in 
which coordination with national authorities responsible for price monitorin~ 
could be organized. In response, the C~ission set up a group of experts on 
drug prices which met infrequently and irregularly2• This committee 'recognized 
the need for information exchanges, coQPer•tion between the authorities at 
Community level, and harmonization of n•tional syste•s· More determined 
action in this field is obviously necessary. 
III.GENERAL FEATURES OF DRUG USE 
1 
A pharmaceutical is more than just another product. Its cost can have a 
considerable impact on public expenditure through the social security system, 
and while ill-considered drug use can be dangerous to health, in certain 
cases self-medication can be highly desirable. The basic features of drug 
use therefore merit serious attention, since they are an integral part of 
a European pharmaceuticals policy geared to improving public health, an 
implicit objective of the EEC Treaty. 
1. Training of medical pract1tiooerp 
The prescription of drugs in. targe numbers ~nd for prolonged periods 
should require more intensive traini~g for Mtdncal practitioners then they 
generally receive. At COMMunity level it would be appropriate to envisage 
post-graduate training in therapeutic techniques and drug control so as to 
enable Community doctors to acquire the necettary expertise and benefit 
periodically from follow-up courses. 
Proposal for a Directive COM<80> 789 final, p.S .-
2 The last meeting of the group was held on 21 November 1980. A CREDOC ~tudy at 
the request of the Directorate-General for the Internal Market concerning 
comparisons of the prices of pharmaceutical products in EEC countries will also 
be published shortly. 
- 20 - PE 77.156/fin. 
The inadequacy of present training entails the risk of ineffective 
excessive or contradictory prescriptions, and of drug-induced illness. 
The development of data banks on drugs, readily accessible to practitioners, 
would also be of considerable value. 
2. User i~formation 
There should also be improvements in the information available to drug 
users. Here the request made in Parliament's motion for a resolution 
(Doc. 1-817/80>1 for the Commission to submit a proposal on a well-
I 
conceived information and education campaign covering the proper use of 
pharmaceutical products and the limits to be placed on their use should 
be reiterated. However, to be effective, any:. such campaign would need to 
be sufficiently decentralized and take account of the varying attitudes 
from one Member State to another of drug users to drugs or to certain 
types of drugs. 
3. Monitoring of distribution methods 
The distribution of pharmaceutical products is frequently criticised. 
A study of current commercial practices in this sector should be carried 
out in order to identify the abuses and eliminate waste due to excessive 
use of pharmaceutical products, harmful side effects and the extra burden 
on social security systems. 
In its previous resolution2 Parliament asked the Commission to submit as 
soon as possible an amended proposal on information and advertising in 
the pharmaceutical industries. The same request was also made in 
Lord KENNET's report3 on a directive on the approximation of legal 
provisions in the Member States on unfair and misleading advertising. 
The Commission's delaying tactics in this field should cease and a 
specific proposal on misleading advertising of pharmaceuticals should be 
submitted. 
As to information disseminated by pharmaceutical company representatives, 
it appears that this remains indispensable at present levels of training 
of medical practitioners. However, improvements in post-graduate training 
of doctors in therapeutic techniques and drug control, together with 
easier access to data banks, could reduce the scope for this type of 
information in future. Abuses by medical laboratories, in particular 
1 Doc. 1-817/80, paragraph 11 
2 Report by Mr DE KEERSMAEKER, Doc. 664/78, resolution paragraph 14 
3 Report by Lord KENNET, Doc. 36/79, resolution paragraph 3 
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1 
the dubious practice of sending gift packages1, $Hould It llt events bl 
severely condemned, and it will be primarily for the Me•ber Statts to 
take appropriate counter measures under national legislation. 
4. Self-medication 
Finally, a strong case can be made for self-medication. The advantages 
of self-medication are manifest: simplicity, lower cost, prophylactic 
effect. But the risks should not be under-estimated. Self-medication 
presupposes a minimum of information and understanding on the part of 
the user, and should in no circumstances be a substitute for prescription 
by a medical practitioner. A Commission study of the advantages and dis-
advantages of self-medication, the standards that should be applied in 
this sector, and specific rules of advertising would be welcome. In 
general, the Community should have access to harmonized and full 
statistics in the pharmaceutical settor as ilt"l ind~spen.sable tool in 
providing regular and accurate informatidn oh tHe use of pharmaceuticals 
and the impact on public health. 
Written question No. 1710/80 on marketing techniques in the pharmaceutical 
sector - OJ No. c 78, 6.4.81, p.19; Written question No. 1709/80 on the 
boycotting of non-proprietary Medicines, OJ C 78, 6.4.81, p.18. 
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MOTION FOR A RESOLUTION DOCUMENT 1-243/80 
tabled by Mr GHERGO, Mr DEL DUCA, Mr SASSANO, Mr DALSASS, Mr BARBAGLI, 
Mr NARDUCCI, Mrs SCHLEICHER and Mrs CASSANMAGNAGO CERRETTI 
pursuant to Rule 25 of the Rules of Procedure 
on the state of implementation of the EEC directives on proprietary 
medicinal products and measures to be adopted for the free movement 
of pharmaceuticals between Member States 
- whereas one of the primary aims of the Community is by appropriate 
measures to ensure the free movement of goods between Member States 
by removing barriers, including non-tariff barriers, which may con-
stitute a de facto obstacle to the export and import of products, 
-whereas the effective application of these principles in the field 
of pharmaceutical products has so far been seriously hindered bi the 
application of the derogations provided for under Article 36 of the 
Treaty of Rome relating to the protection of health and Life of humans, 
- whereas, in contrast with the principles underlying the provisions of 
Article 36 of the Treaty of Rome, the application of these derogations 
in the pharmaceutical field often Leads to an actual reduction in the 
protection of health, either because the opportunity for the entire 
population of the Community to use new and more effective products to 
treat diseases, is prevented or considerably delayed or because products 
remain in circulation in some Member States after other Member States 
have found them to be potentially harmful, 
- whereas Article 100 of the Treaty of Rome provides a means of overcoming 
these barriers by the harmonization of national Legislation, 
whereas the Council has so far adopted four important directives in 
the pharmaceutical sector covering inter alia the procedures for bringing 
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products on to the m1rket, the stand,rds and technicaL -~tJ 
re9uired for proprie~ary m'qi~infL products, thtt ~ab,L$ 'nd ln.stru~ti~s 
~~r ~~! pf ~~'~'products· a~~ the setting up of th1 Co~i~~'' ~~r 
Propri,tfry ~edicinal Products, 
:- h~vins particular regard to the important role of this co•ittee j!' 
i~P.~~menting Article 14 of Directive 75/319 regarding consultation~ 
' -
~~ Community level by individual Member States before they reach a 
decision on a marketing authorization for a medicinal product or its 
' 
r~vocat ion, 
- whereas, under Article 15 of Oirectiv' 75/J19, the Commission has 
to submit proposals to the Council br th• ,~of 1980 containing all 
appropriate measures leading towarqt, fh, ~P9~ition of_ any remaining 
barriers to the free movement of P.r~pri,~pr~ ~~icinal products, and 
w~ereas it would be extremely desif~~~~ fQf ~~-·e proposals to be 
given their first consideration ~~~ t~t mtxt •~•ting of the Council 
of Ministers of Health, 
- .not'ing that the obstacles to th, frtt !IIO~mnt c:?f medicinal products 
' • • , I' 'I•• > ,, ,J I. •! , ; 
affect the availability of som~ pf~~FU w~~~h 're needed to treat_ 
serious, though perhaps rare, di~,,~,sr ~;~~- t~e limited size of.the 
market and of consumption doe~ not erco4rt9' r,search and experimentation 
into __ !ljch- ~u~stan~es n~_r ~h_!~!_!!fO~u~tit?fit 
. recognizing, therefore, the ne~~ ~q rtl!l~\tf ~~!' parriers·. which hav.,_ arisen 
to the free movem~nt of propriet~rY ~,dicin•~ products, 
- rtcognizing also the need f~r ~n~ ~~f9R'~~ P-~r~i~~ent, as the expression 
of popular will in the Me,~r ~t~~'S.r tQ ~~ ~~~~'~ inforaed about all 
the issues concerned wit~ ~h~ fr~P !Jiqlf""'~'!'lt qf these products, in v.iew, 
for example, of the close links thi$ has with the protection of health, 
' > 
1. Requests the Commission ~Q ~'HP!IIH ~ f4H report at the earliest"' 
opportunity on the s~~t' pf .i~leJII~Pt~t~rm pf -t~e directives wh-ich 
have already been a~p~~~q in ~p~ p~ar~ac,utiF.fl s•ctor, giving 
particul-ar attention to ~n~ dfffitulties or obstacles which may 
have arisen in the op~r~tion qf the Commjttee for Proprietary 
Medicinal Products; 
• , r 
2. Considers that furth•r ~''~r'' n•~d. ~o ~ t~k'n i~ ~~is area so as 
to permit the fr•e ~~,~~~~ of phfr••ce~tic.Lt within the CoMmunity 
even if this has to be done in st~~es~ 
-·24 -
3. Considers that to this end further steps must be taken towards the 
harmonization of Member States' legislation on the production, 
authorization-registration and distribution of proprietary 
medicinal products; 
4. Considers that, as part of this general process, measures should 
be adopted as a matter of urgency to make Community action more 
effective in regard to decisions taken by the Member States on 
authorizations for proprietary medicinal products or revocations 
thereof particularly where there are good grounds for believing 
that products may be harmful; 
5. Identifies as one of the first measures to be adopted - until 
such time as Liberalization is achieved and as part of the progress 
in stages referred to above - a di~ective to permit the free movement 
within the Community of medicines required for the treatment of serious, 
but rare diseases, by including them on a special, limited List of 
products to be drawn up and brought regularly up to date by the 
Commission with the aid of specialized advisory technical bodies; 
6. Requests the Commission in conclusion to draw up with the greatest 
possible urgency suitable proposals on the subjects indicated above, 
so as to allow Parliament to express its opinion on them and the 
Council to adopt at the earliest possible time the relevant measures 
which should have a binding force on the Member States. 
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MOTION FQR A RESOLUTION DOCUMENT 1-817/~0 
t~~Ltd by Mrs KROUWEL-VLAM, Mr COLLINS, Mrs SEIBEL-EMMERLING, Mr _,._, 
Mrs FUILLET, Mr MUNTINGH, Mr O'CONNELL, Mrs. ROUOY, Mrs WEBER 
on behalf of the Socialist Group 
pursuant to Rule 25 of the Rules of Procedure 
on the production and use of pharMaceutical products 
- whereas the right to optimum health care is • fundaMental right, 
- whereas public health falls with t~• scepe qf ~he Treaties 
- whereas it is the task of Member St•t•• and the Ca..unity to provide 
t~e.selves with structures guar1ntttint the ~at possible health care, 
- whereas the growing use of phar•apeutical pr~cts leads to high costs 
for social se~uritY systems, 
~ whereas phar .. teutical production is in the hands of a few large 
undertakings which occupy a dominant positiQn and aake enorMOUs 
profits at th* Community's eKpen,e, 
- whereas the Community directiveS. ad~pted on thiJ subject chiefly 
concern the free moveMent of phar•aee4tical products, which is, however, 
still seriously impeded.by technical barrier• to trade, 
1. Is concerned at the uncontrolled iricreaee in tf\e n~ber of pharliiaceutical 
products being put on the Market and the variety of forms in which they 
appear, without any evidence thlt this quantitative increase is 
producing a perceptible im,rove•ent in the qu•lity of health or 
health protection; 
2. Considers that Measures need to be taken again$t the overconsUMption 
of pharmaceutical products due to ComMercial practices, in particular 
advertising by pharmaceutical Laboratories, so as to prevent the 
wastage, harmful side effects and extra burden on the social secur.ity 
systems; 
- _26.-
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3. Stresses the need for a transparent marftttt f.or pharma-ceutical prodwcts 
by means of quality and pr.ice controls in order to put a stop to 
excessive· pn!ITi·ts; 
4. Points out the existence of, and ~rade in, illegally imported products 
and· ~rgent ly requests the Commission to start 1;he necessary inv.esHgatton 
and to tak'e effective action; 
5. Is .of the opinion that the price of pharmaceutical products ·ought 
not to be allowe:d to become a social obstac~e to the right to optimum 
health care; 
6. Stresses therefore the need for the strict application on the rute.s 
of competition; 
7. Recalls the need to reorientate poli-cy regarding pharmaceutical products 
so that· industrial interests are no Longer the only matter to wh..;ch 
importance is attached but also coordination between J)harmac~tical 
Laboratories, private and government research inst.itutes and the do-ctors 
concerned, in the interests of the consumer; 
8. Urges the rapid harmonization and raising of standards in registration 
of pharmaceutical products so that the differences between Member 
States as regards what products are available on or off prescription 
cease to exist; 
9. Is of the opinion that the consUMer is entitled to verified information 
on the packaging and enclosures; 
10. Requests the Commission to proceed without delay wi.th its proposal on 
misleading advertising for pharmaceutical products; 
11. Considers it essential that a proposal be received from the Commission 
in the near future on a well-conceived information and education campaign 
covering the proper use of pharmaceutical products and the limits to be 
placed on their use; 
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12. Urges that more attention be paid to the points mentioned above in 
training and further training courses for doctors, nursing staff and 
pharmacists,'so that all persons using or prescribing medicines have 
available aH the necessary information on the therapeutic value of 
the products proposed to them; 
13. Deplores ttie way in which many pharmaceutical companies, through their 
medical representativ,es, frequently see fit to offer their products 
for sale to ~octors by means of samples, gifts and loans, and calls 
on the Commission to draw up a proposal designed to prevent the use 
of these. imi>roper sales pract·; ces. in the var'ious Member States; 
14. Considers that pharmaceutical products exported to developing 
countries. must satisfy the same safety and quality standards .as those 
applicable in the-,:Melllber States of the Community; .: 
15. Instructs the Colllflli_ssion to harmonize the statistical information 
completely and to analyse this in ~ report on the pharmaceutical 
seet'Or, so'that a soiJnd'overall picture may be gained of the 
consumption of pharma~utical products and the consequences thereof 
for public health. 
'. 
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OPINION 
of the Committee on th~ EnviL·onment, Public Health and Consumer 
I Protection I -- --
Draftsman: Mr SHERLOCK II .• 
- · , ::- 111}~-:-: .:-~ !.981 the ro~!':litte.c -!"' the Envi::-cnm::!n+:: F·_::.:..i::; 
Health and Consumer Protection appointed Mr SHERLOCK draftsman. 
The draft opinion was considered at its meetings of 25 May 
and 23 June 1982 and adopted unanimously on 23 June 1982. 
The following took part in the vote: Mr Collins, chairman; 
Mr McCartin, vice-chairman; Mr Johnson, vice-chairman; 
Mr Sherlock, draftsman; Mr Bombard, Mr del Duca, Mr Forth, 
Mr Ghergo, Mrs Krouwel-Vlam, Mrs Lentz-Cornette, Mr Muntingh, 
Mrs Schleicher, Mrs Seibel-Emmerling, 'Mrs Spaak, Mrs van Hemeldonck 
and Mr Verroken (deputizing for Mr Alber). 
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I. INl'ROOUCl'ION 
1. The Catmittee on the Environnent, Public Health and Consumer Pr~~ ~ 
been ask..ec;l for its opinion on the production and use of phannaceutical .~ 
. . /. ' 
in the C~ity as a result of the ~Wtions for resolutions subnitted by :* .~ 
and ~lrs ~~1-VlarQ pursuant to Rule 25 (Doc. 1-243/80 and 1-817/80). 
2. In the ,case of Mr Ghergo's trotion for a re;1o~~tion the carmittee has ~~ 
set out its position during consideration of ~ ~dments proposed by the 
-~cmnission to Directives. 65/65/EEC, 75/318/~ ~· 75/319/EEX: on the apprax:i.lna1;ion 
,;: ?:-ovisi911s laid doNn by law, regulation .9F ~rative action relating to 
•.::c: . .r;. ·'.etaL~' rne·:Hc1nal products (see Dc:x::. ~~/4V,(WP.·). 
·;. l\s rPq.ards the motion. for a resolut~qt? fiif ~.f ~~1-Vlam, the camittee 
.... ould like to point out that the above-.~~~ .cn~t~ves on medicinal products 
io t.hc F.ur(Ji)l'~an Ccmnunit.y alre(ldy goverJ;l tRe, t:pl~Q!ffUlq: 
a. ;conditions for the granting, suspq~~~ .~~W~~awal of authorizations 
I 
; for the marketing of proprietary ~41Ff.n4l fi?FRtH;~; 
'J: ·the conditions with which each prod:qq: f.9J: ~#:h ~ authorization is granted 
I . 
. must carply; 
c. :the specifications for testinq ~d ~n~~~·t~ m,>Pl.ications for authprizaticns 
I , " 
for the marketing of proprietary ~~~~1 p~~s: 
the specification~ for labels ~d ~cc~inq information: 
the tasks of the public authQr~~~~e~ r~~sip.~f' F~~ checking and supervisiCII'l; 
Tt:e Council Decision of 10 May 1~78 (7$/l~9~) provided for the creation 
. ~~·-·~, cc ~-=-:.. , ... rvpr~e·cary ~c~~.~t P-,:~r.t; ~ ~·~~ .:ooperatlOa1 bet>'lt::an 
·~ropr:ate national autbo~itt~~ ~ .~ .~~1 ~~siqn of 20 May 1975 
:.,--: .. :.0/?:i:l.:.) provided for the cre4~ipn p' !l ~'J~j.,<rp+ Cqnnittee made up of 
sr.;:nior civil servants fran t.J'l1! ~r ~t~~ ~ ~!i#, iJ: ~s to advise the 
Carmi.ssion on general quesst~ons ~lll.j.~ p,~i~ ,.Uci.nal procllcts. 
, I 
I 
::.. PR<nX:TIOO J\ND USE \)f HEDJCINN,:. PROI:lOCTS 
- -·- ----- __ ...__~ . ...;....,.. ;.-.;~ 
'· The Catrn.ittee on the Emriror~m~, Pub,J.~c l)ftal~ ~ Con8\ill¥.!r Protectioo ~ld 
·- ~e to start by recalling its fr~n~l-¥ ~esMd v_iew that any regulation con-
~erning the pfoduction and d.istri,QtJt.iop pf ~inal p~ocllcts rrust have as its 
prirre aim the protection ~d foste~.i "9 of publ~c ~th, ev,en ~ the industricll · · 
·.!.::d ccmnercia: aspects ~y }:)e ve.rr infl\.l.ential. 
P.E 77 .8~/(in. 
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6. 'lhe ccmn.itt£~ tDkes it as read that nedicinal products must be as effective 
as possibler have the mininun negative effects and be as ~onanical as possible. 
Without going into·greater detail on this point, it seems obvious to the ccmmittee 
that these three objectives cannot be achieved without sufficient encouragerrent 
of the necessary scientific research. 
7. Con~qucntly we !.;hould <~lso n!Call the rrceting of lf) Noverri.:Jer 1978 of the 
Council of Ministers of Health which noted with .interest the three studies 
carried out by the Ccmnission on the cost of health services. One of these 
concerned the consumption of phan&~cutical products and was compiled by 
Mr B. Abel-Smith and Mr P. Grandjeat1 • 
·-
a. t:hat during the period under review ( 1966-1975) there was a decrease in the 
total consumption of prescribed pharmaceutical products expressed as a pro-
portion of total health service C<h~ts in seven Member States (no statistics 
were ayail<ilile for ·rrcland and Belgium) (Annex ·1) .: 
b. that an unusually large disparity was ascertained in the average nunt>er of 
rredic inal products prescri.bed per person per annum which varied fran 4. 5 
in the Netherlands (1974) to 21.5 in·Italy (1975) (Annex II, Table II); 
c. the following reasons were given for the increase in the cost of phanna-
ceutical products: 
- population growth 
- expansion of health insurance scherres 
- change in the population age pyramid 
- changes in production and distribution costs 
- the replacerrent of older medicinal products by newer, more ~~nsive ones 
..::n~1gt;s .1..11 ~..ne nurrtlcr of consultatior~s 
-· :::hangcs in roodieal practice. 
9. Taking account of these elerrents and the fact that ~upply and demand is 
anything but transparent in the pharmaceuticals sector, and that market splitting 
and sametL~s a great diVergence in prices are more in evidence than a common 
market, the Ccmnittee·on the Envir~nt, Public Health and Consumer Protection 
believes that there is every justification for further investigation cf the 
situation. 
1
studies: Social policy series 
I 
I 
1~78 - N° 3 ( 
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lO, It therefore asks the committee responsible to recommend the following in 
its report: 
=. an investigation into whether the trends in the pharmaceuticals sectm: 
~scertained for tlle period 1966-1975 also apply to the period 1976-1981; 
! . 
c... clln i.nvestigation. into how a .st<1rt can be made on the sale of medicinal 
products under generic names, so as to benefit consumers in terms of 
both price and availability; 
r, view of very aivergent national views, an apprai~l of whether a 
.sectoral dirc..-ctivc on advcrtisinq of phar.maceutical products is necessary; 
(self-:rcdication) and those which should be strictly subject to prescription; 
a guarantee that, in promoting the free mov~ment of pharmaceutical products. 
the elcrent of protection of public health should not be lost by allowing 
tx'ssibly less stringent legislation on the admissibility, supervision or 
proh.ibition of certain rrcdicinal products'or conflicting decisions on the 
approval of dosoges, i~structions and contra-indications for medicinal 
products; 
f. an investigation into ways of curbing excessive consumption; 
g. an investigation into whether a European information .and ·action 
programme on the prescription and use of medicinal products could 
improve public health and save costs; 
h. an investigation into what results from the Council of E~rope's 
deliberations could be used in European legislation; 
i. a request to the Commission to report each year on progress ~n c,e 
harmonization of pharmaceutical products; 
j. an instruction to the C~mmission to work out a system whereby the 
statistical information on the costs and use of pharmaceutical products 
in the Member States can be compared 
- 32 -
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CCtn.USIOO 
11. 'Ihe. Catmi.ttee on the Environment, Public Health and Consumer Protection 
believes that, with a view to the realization of a common market in the interest 
, ... t,·,lJ.Jlic health, the question of the procluctim and use of pharmaceutical pro-
ducts, which naturally has considerable financial inplications, calls for con-
siderable further investigation and is in fact too dependent oo the different 
social security schemes in the Merrber States. At the sane time it believes 
that ~~isting Community provisions must be amplified in the near future tO cqver 
.:.~ mut'4al recognition of rore stringent national decisions, 
~names for ~eutical products, a methodology for the catpila-
~ion of statistics, self-medication and proper inf~tion on the use of 
,nedic ines. 
- 33 - PE 77 .856/f1n • 
• _j 
I. 
·W 
~ 
• 
.. 
Estimates of total consumption of prescribed pharmaceuticals (including 
tax) as a percentage of estimates of the cu,rrent cost of health services 
(1) (including tax) - EEC 1966-1975 
Denmark Germany France Italy(2)(3) Luxembourg(2) NetherlanQ.s(4) 
1966 12.6 14.3 24.3 51.1 39.2 
1967 12.9 24.5 49.4 39.6 
1968 12.8 15.6 24.8 49.7 39.8 
1969 12.5 24.2 47.4 40.1 
1970 12.0 16.0 24.3 42.6 34.7 ( 11.0} 
1971 12.0 24.4 39.9 38.1 
1972 11.8 14.9 23.8 37.8 36.6 (11.0} 
1973 10.9 -22.7 38.6 36.0 (10.6) 
1974 10.4 13.9 21.8 28.9 34.2 ( 9.9) 
1975 10.6 13.3 21.0 34.5 26.1 ( 9 .. 7) 
(1) Excludes products made up by pharmacists 
(2) Includes cost of hospital pharmaceutical departments in whole or part 
( 3) Includes only registered products in the case of non-prescription medicines 
( 4) Excludes drugs prescribed in hospital. 
"Percentages 
United Kingdom 
(England a Wales only) 
12.4 
12.3 
12.0 
12.1 
ll.S 
11.8 
12.0 
11.8 
10.9 
10.5 
f 
~· ~· 
l' 
Doctors per 10.000 population, ave·raqe prescription items per person per year, 
and pharmaceutical consumption as a proportion of the cost of health services 
Doctors per 10,000 population Prescription Items Per Person Pharmaceutical Consumption 
(1) per year under Health Insurance 
Netherlands 
United Kingdom 
(England & Wales) 
Denmark 
Belgium (3) 
France (3) 
Germany 
Italy (3) 
(1975) 
16.0 
13.1 
16.2 (1972) 
18.9 
14.7 
19.4 ( 1974.) 
19.9 {1973) 
(1) Sources - WHO, Annual Statistical Summaries 1965 and 1~77 
(2) Only covers prescription drugs outside hospital 
or the Health Service 
(1975) 
4.5 {1974) 
6.3 
6.9 (1976) 
9 
10.5 
11 (1973) 
21 ( 4) 
(3) Including doctors practicing dentistry of specialists in odontology 
{4) For doctors paid on fee-for-service basis 
as a P.ercentage of Cost of 
Health Services 
{1975) 
9.5 ( 2) 
13.8 
11.7 (1974) 
19.5 
25.5 
18.8 {1974) 
34.6 
• 
